Efficacy and safety of potassium-competitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: a meta-analysis of randomized clinical trials
Open Access
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The binding selectivity of vonoprazan (TAK‐438) to the gastric H+,K+‐ATPaseAlimentary Pharmacology & Therapeutics, 2015
- Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible BenefitsGastroenterology, 2015
- Vonoprazan: First Global ApprovalDrugs, 2015
- Helicobacter pylori: perspectives and time trendsNature Reviews Gastroenterology & Hepatology, 2014
- Helicobacter pylori research: historical insights and future directionsNature Reviews Gastroenterology & Hepatology, 2013
- The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012Gastroenterology Research and Practice, 2012
- Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut, 2010
- Peptic ulcer diseaseThe Lancet, 2009
- Meta‐analysis: high‐dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradicationAlimentary Pharmacology & Therapeutics, 2008
- New concepts of resistance in the treatment of Helicobacter pylori infectionsNature Clinical Practice Gastroenterology & Hepatology, 2008